| abstract |
The present invention relates to phenylaminopyrimidine bicyclic compounds of formula I, which are inhibitors of protein kinases, including JAK kinases. In particular, the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. Kinase inhibitors can be used to treat kinase-related diseases such as immunological and inflammatory diseases including organ transplantation; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. |